Details for New Drug Application (NDA): 062755
✉ Email this page to a colleague
NDA 062755 describes NALLPEN, which is a drug marketed by Glaxosmithkline and Baxter Hlthcare and is included in three NDAs. Additional details are available on the NALLPEN profile page.
The generic ingredient in NALLPEN is nafcillin sodium. There are eleven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the nafcillin sodium profile page.
The generic ingredient in NALLPEN is nafcillin sodium. There are eleven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the nafcillin sodium profile page.
Summary for 062755
| Tradename: | NALLPEN |
| Applicant: | Glaxosmithkline |
| Ingredient: | nafcillin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062755
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Dec 19, 1986 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL | ||||
| Approval Date: | Dec 19, 1986 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
